Patents by Inventor Janine FAIGLE

Janine FAIGLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP
    Publication number: 20240117049
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA
  • Bispecific antigen binding molecules targeting OX40 and FAP
    Patent number: 11780919
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: October 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Juergen Peter Bachl, Alexander Bujotzek, Carina Cantrill, Harald Duerr, Janine Faigle, Sabine Imhof-Jung, Christian Klein, Thomas Kraft, Estelle Marrer-Berger, Ekkehard Moessner, Laurene Pousse, Petra Rueger, Johannes Sam, Roland Staack, Dietrich Tuerck, Pablo Umana, Joerg Zielonka
  • BISPECIFIC ANTIBODIES COMPRISING A MODIFIED C-TERMINAL CROSSFAB FRAGMENT
    Publication number: 20230227584
    Abstract: The present invention relates to bispecific antibodies comprising a modified C-terminal crossfab fragment that have reduced or no reactivity against preexisting antidrug antibodies.
    Type: Application
    Filed: September 30, 2022
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Ali BRANSI, Peter BRUENKER, Janine FAIGLE, Sabine IMHOF-JUNG, Roland STAACK, Joerg ZIELONKA
  • BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP
    Publication number: 20220025046
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 31, 2021
    Publication date: January 27, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA